Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

lansoprazole

APO-LANSOPRAZOLE

lansoprazole (APO-LANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved NMPA: clinical trials
US status approved
Patents linked 12
Pipeline programs 36
News articles 0
Drug details — lansoprazole
US status
approved
Class
—
Route
ORAL
Patents
12
Programs
36
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

lansoprazole (APO-LANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN lansoprazole
Brand APO-LANSOPRAZOLE
Mechanism Potassium-transporting ATPase inhibitor
Target Potassium-transporting ATPase
Route ORAL
Formulation CAPSULE, DELAYED REL PELLETS, TABLET
Originator Pfizer Australia Pty Ltd

Mechanism of action

Potassium-transporting ATPase inhibitor

Primary target: Potassium-transporting ATPase

Approval history

Authority Status Date
FDA approved —
TGA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. CX842A2301 Phase 3 · Anaxis Pharma · Erosive esophagitis (EE) due to gastroesophageal reflux dise
  2. CX842A2303 Phase 3 · Anaxis Pharma · Erosive esophagitis (EE) due to gastroesophageal reflux dise
  3. Dexlansoprazole Phase 3 · Takeda · Heartburn
  4. Dexlansoprazole Phase 3 · Takeda · Erosive Esophagitis
  5. Dexlansoprazole Phase 3 · Takeda · Gastroesophageal Reflux
  6. Dexlansoprazole MR Phase 3 · Takeda · Esophagitis, Reflux
  7. Dexlansoprazole MR Phase 3 · Takeda · Gastroesophageal Reflux Disease
  8. Dexlansoprazole MR QD Phase 3 · Takeda · Gastroesophageal Reflux

Related & competitor drugs

Browse all drugs
  1. dexlansoprazole Potassium-transporting ATPase inhibitor
  2. esomeprazole magnesium Potassium-transporting ATPase inhibitor
  3. omeprazole Potassium-transporting ATPase inhibitor
  4. pantoprazole sodium Potassium-transporting ATPase inhibitor
  5. rabeprazole sodium Potassium-transporting ATPase inhibitor
  6. vonoprazan fumarate Potassium-transporting ATPase inhibitor

Related patents

Browse patents Pfizer Australia Pty Ltd patent hub

  1. US 9114085

    Modified release pharmaceutical compositions of dexlansoprazole

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8758818

    Oral tablet compositions of dexlansoprazole

    Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8753682

    Dual release oral tablet compositions of dexlansoprazole

    Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8741345

    Modified release pharmaceutical compositions of dexlansoprazole

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8563034

    Dual release oral tablet compositions of dexlansoprazole

    Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8563035

    Oral tablet compositions of dexlansoprazole

    Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7678816

    Method of stabilizing lansoprazole

    Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7622588

    Method for the purification of lansoprazole

    Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7285668

    Process for the crystallization of (R)- or (S)-lansoprazole

    Expires Mon Oct 18 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7060837

    Method for the purification of lansoprazole

    Expires Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7022859

    Method for the purification of lansoprazole

    Expires Mon Mar 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  12. US 6909004

    Method for the purification of lansoprazole

    Expires Mon Jun 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is lansoprazole?

lansoprazole (APO-LANSOPRAZOLE) is a potassium-transporting atpase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for lansoprazole?

APO-LANSOPRAZOLE is a marketed brand name for lansoprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lansoprazole?

lansoprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.